AndroGel and Rivaroxaban Interaction: What Patients and Clinicians Need to Know
HealthRX.com
No documented AndroGel and rivaroxaban interaction found
Key numbers
- 3.0%Mean hematocrit rise with testosterone gel vs placebo across 29 randomized trials in 3,393 menSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 4.0%Mean hematocrit rise with intramuscular enanthate or cypionate vs placebo across 29 randomized trials in 3,393 menSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 1.7% versus 1.2%VTE in TRAVERSE: 1.7% with daily 1.62% gel vs 1.2% with placebo gelSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
From the public record
FDA adverse event reports listing both rivaroxaban and testosterone
Through 2026-10-28, FDA had received 446 adverse event reports that list both rivaroxaban and testosterone, out of 193,780 reports for rivaroxaban and 41,579 for testosterone. A joint report shows both were recorded for the same person, not that they interacted.
| Measure | Value |
|---|---|
| Reports listing both drugs | 446 |
| All reports for rivaroxaban | 193,780 |
| All reports for testosterone | 41,579 |
| Joint reports naming fatigue | 30 |
| Joint reports naming diarrhoea | 24 |
| Joint reports naming gastrointestinal haemorrhage | 23 |
| Joint reports naming pulmonary embolism | 21 |
How this was calculated
Counted FAERS reports that list both active substances in any role, then the symptom terms named most often in those reports. Terms about product use rather than symptoms were left out. The events may relate to either drug, to another drug, or to the illness.
Reports listing both rivaroxaban and testosterone as single-ingredient active substances, any brand, suspect or concomitant
FAERS reports are unverified and do not prove the drug caused the event. Reporting rises with use, publicity and lawsuits, so these counts cannot give rates or risks and cannot be compared between drugs. Joint reports are not evidence of an interaction.
From the public record
Published papers mentioning both testosterone and rivaroxaban
PubMed indexes 7 papers whose title or abstract mentions both testosterone and rivaroxaban, 6 of them published from 2016 to 2025. For comparison, 103,536 papers mention testosterone and 9,513 mention rivaroxaban.
| Measure | Value |
|---|---|
| Papers mentioning both | 7 |
| Of those, published 2016 to 2025 | 6 |
| Papers mentioning testosterone | 103,536 |
| Papers mentioning rivaroxaban | 9,513 |
How this was calculated
Ran one PubMed title and abstract search requiring both names, and one search for each name alone. No filtering by study type or quality.
PubMed records naming both substances in the title or abstract, all article types and species
A paper that mentions both is not necessarily a study of their interaction, and may report no interaction. Counts include animal, cell and review papers.
At a glance
- Rivaroxaban class / Direct factor Xa inhibitor, an oral anticoagulant (not a vitamin K antagonist) [4]
- Anticoagulant entry, generic 1.62% gel label / Androgens may change anticoagulant activity; more frequent INR and prothrombin-time monitoring recommended; no anticoagulant named [1]
- Xarelto label on monitoring / Monitoring its anticoagulant effect with PT, INR, aPTT or anti-factor Xa tests is not recommended [4]
- Hematocrit checks, generic 1.62% gel label / Before treatment, 3 to 6 months after starting, then annually [1]
- Mean hematocrit rise with gel / 3.0% vs placebo across 29 randomized trials, 3,393 men [2]
- VTE in TRAVERSE, 1.62% gel vs placebo / 1.7% vs 1.2% [1]
What the testosterone gel label says about anticoagulants
AndroGel is a topical testosterone gel, and 1.62% is one of its strengths. The label text discussed on this page is a generic 1.62% testosterone gel label, not AndroGel's own label. Its drug interactions section lists insulin, oral anticoagulants and corticosteroids. The anticoagulant entry says changes in anticoagulant activity may be seen with androgens, so more frequent monitoring of international normalized ratio (INR) and prothrombin time is recommended in patients taking anticoagulants, especially at the start and end of androgen therapy [1]. The entry names no specific anticoagulant [1].
Questions worth asking
What the Xarelto label says
Rivaroxaban inhibits factor Xa. It is cleared by CYP3A4/5 and CYP2J2 metabolism plus P-glycoprotein and BCRP transport [4]. The Xarelto label says it can cause serious and fatal bleeding, and that aspirin, P2Y12 inhibitors, other antithrombotics, fibrinolytics, NSAIDs, SSRIs and SNRIs raise bleeding risk. It also says monitoring the anticoagulant effect with PT, INR, aPTT or anti-factor Xa tests is not recommended [4]. The INR and prothrombin-time advice in the testosterone gel label is therefore written generally for anticoagulants, and the Xarelto label does not use those tests to follow rivaroxaban.
Hematocrit: what the generic gel label asks for and how big the effect is
The polycythemia section of the generic 1.62% gel label says to check hematocrit before starting treatment, re-evaluate it 3 to 6 months after starting, and then check it annually. It says that if hematocrit becomes elevated, therapy should be stopped until it decreases to an acceptable concentration, and that an increase in red blood cell mass may increase the risk of thromboembolic events [1]. It describes an acceptable concentration rather than a specific number [1].
The average change is modest but real. A network meta-analysis of 29 placebo-controlled randomized trials in 3,393 men found that testosterone gel raised mean hematocrit by 3.0% versus placebo (95% CI 1.8 to 4.3), and intramuscular enanthate or cypionate raised it by 4.0% (95% CI 2.9 to 5.1) [2].
Venous thromboembolism appears separately in that label. It notes postmarketing reports of deep vein thrombosis and pulmonary embolism with testosterone products. In TRAVERSE, which randomized 5,246 men to daily 1.62% gel or placebo gel [3], VTE occurred in 1.7% versus 1.2%, DVT in 0.6% versus 0.5%, and PE in 0.9% versus 0.5% [1].
What the generic gel label says to watch for
That label says pain, edema, warmth and erythema in the lower extremity should prompt evaluation for DVT, and acute shortness of breath should prompt evaluation for PE. If a venous thromboembolic event is suspected, the label directs discontinuation of the gel and appropriate workup [1].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Can I take AndroGel with rivaroxaban?
Does rivaroxaban need INR checks?
How often does the gel label say hematocrit should be checked?
Does the gel label name rivaroxaban?
How much does testosterone gel raise hematocrit?
What clot symptoms does the gel label describe?
References
Show all 4 referencesHide references
- U.S. National Library of Medicine, DailyMed. Testosterone gel 1.62% topical, generic (Padagis), the AndroGel 1.62% formulation type prescribing information. Testosterone gel 1.62% topical, generic (Padagis), the AndroGel 1.62% formulation type label
- Nackeeran S, Kohn T, Gonzalez D, White J, Ory J, Ramasamy R. The Effect of Route of Testosterone on Changes in Hematocrit: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Trials. J Urol. 2022;207(1):44-51.
- Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117.
- U.S. Food and Drug Administration. Xarelto (rivaroxaban) prescribing information, label effective 2026-09-10. Drugs@FDA: FDA-Approved Drugs